EHT501

EHT501 is an experimental drug candidate being developed by Euhearing Therapeutics for the treatment of acquired hearing loss. This condition includes hearing impairment resulting from external factors such as noise exposure, ototoxic medications, or the natural aging process (presbycusis). Within the Euhearing Therapeutics pipeline, EHT501 is categorized as a pharmacological treatment for acquired conditions, distinguishing it from the company's gene therapy programs (such as EHT101) which target congenital monogenic deafness. As of 2024, EHT501 is in the early research and preclinical stages of development, and while specific molecular targets have not been publicly disclosed, the program likely focuses on hair cell protection or regeneration within the inner ear.